Fecal microbiota transplantation combined with sintilimab and SOX as first-line treatment for advanced gastric cancer (FMT-JSNO-01): A prospective, multicenter, double-blind, randomized placebo-controlled phase II trial

• Published in: Journal of clinical oncology Vol. 43; no. 16_suppl; p. TPS2702
• Main Authors: Xue, Ya, Wang, Qiong, Zhou, Xuefeng, Zhang, Ling, Guo, Qing, Wang, Chunbin, Li, Xiaoqin, Jiang, Hua
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2025

TPS2702Background: Chemotherapy in combination with immunotherapy has emerged as the first-line(1L) standard of care for gastric cancer (GC) patients(pts); nonetheless, the overall prognosis remains suboptimal. Fecal microbiota transplantation (FMT) holds promise in modulating the patient's gut...